Chardan initiated coverage of Centessa (CNTA) with a Buy rating and $30 price target The firm assumes the company’s lead product ORX750 could be the best-in-class product for the treatment of narcolepsy and other sleep disorders and generate over $2B peak sales in the U.S. Centessa also has multiple follow-up compounds to pursue other large neurological and neuropsychiatric disorders, “which would provide additional upside to the story,: the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Centessa Pharmaceuticals’ ORX750: Promising Developments and Buy Rating by David Risinger
- Centessa initiated with an Overweight at Piper Sandler
- Centessa Pharmaceuticals: Promising Potential in Neuropsychiatric Disorders with ORX750 and Orexin Agonist Pipeline
- Centessa Pharmaceuticals: Promising Orexin Pipeline and Strong Financials Drive Buy Rating
- Promising Potential of Centessa Pharmaceuticals’ Orexin Agonist Pipeline Drives Buy Rating